Controlled nucleation: Driving consistency and efficiency in pharmaceutical freeze-drying

In pharmaceutical manufacturing, freeze-drying (lyophilisation) plays a pivotal role in ensuring product stability, especially for biologics and injectable formulations. Yet, uncontrolled ice nucleation during freezing introduces significant variability. Stochastic freezing and the effects of supercooling can be unpredictable and impact product uniformity, drying efficiency, quality, and in some cases product degradation.

ControLyo® overcomes this limitation by enabling precise, simultaneous ice nucleation across all vials via an inert gas pressurisation step followed by rapid depressurisation to trigger controlled crystallisation at a defined temperature. The benefit being the creation of larger, more uniform ice crystals that sublimate more efficiently and consistently – improving both product performance and process predictability.

Strategic Benefits Across Functions

For R&D leaders across the pharma industry, ControLyo® provides a reliable platform for formulation development, which minimises variability in critical process parameters, supporting faster scale-up and more robust tech transfer. It also reduces the stress conditions that often lead to protein aggregation, helping maintain the integrity of sensitive biologics.

From an operations perspective, the impact is equally compelling. ControLyo® has been shown to reduce primary drying time by as much as 30–40%, translating into increased throughput, greater manufacturing efficiency, and reduced energy consumption. More consistent drying behaviour across vials enhances batch uniformity, minimises reprocessing risk, and simplifies validation.

For process and validation engineers, ControLyo® integrates seamlessly into both development-scale freeze dryers like the LyoStar 4.0 and GMP compliant clinical manufacturing systems such as the LyoConstellation models, without the need for formulation additives or excipients.

As the demands and expectations of freeze-drying requirements increase - driven by complex biologics, personalised medicine, and tighter regulatory expectations -, technologies like ControLyo® offer a clear path to improved performance and compliance. By bringing control to one of the most unpredictable steps in lyophilisation, ControLyo® from SP (an ATS company) enables pharmaceutical & biotech manufacturers to deliver higher-quality products, faster and more reliably.

Need to discuss your requirements? Speak to a specialist at Biopharma Group.

More information online